Copyright
©The Author(s) 2016.
World J Anesthesiol. Mar 27, 2016; 5(1): 15-27
Published online Mar 27, 2016. doi: 10.5313/wja.v5.i1.15
Published online Mar 27, 2016. doi: 10.5313/wja.v5.i1.15
Ref. | Painful syndrome | Study design | Number of patients | Coil | Site stimulation | Frequency, intensity, n sessions | Outcomes | Efficacy |
NP | ||||||||
Lefaucheur et al[26] | Intractable neurogenic pain | Double-blind, controlled, crossover | 18 | F8 | Hand M1 | 0.5-10 Hz | Pain intensity | Analgesic effect (only for 10 Hz) |
(12 central NP; 6 peripheral NP) | 80% RMT | |||||||
1 | ||||||||
Lefaucheur et al[116] | Pain due to thalamic stroke or trigeminal neuropathy | Double-blind, controlled, crossover | 14 | F8 | Hand M1 | 10 Hz | VAS | Decrease in VAS |
(7 central NP; 7 peripheral NP) | 80% RMT | |||||||
1 | ||||||||
Rollnik et al[41] | Chronic refractory NP | Double-blind, controlled, crossover | 12 | Double coin - Circular coin | M1 | 20 Hz | VAS | No effect |
(2 central NP; 7 peripheral NP; 2 CRPS; 1 osteomyelitis) | 80% RMT | |||||||
1 | ||||||||
Lefaucheur et al[27] | Pain do to thalamic stroke, brainstem stroke, spinal cord lesion, brachial plexus lesion, or trigeminal nerve lesion | Double-blind, controlled, crossover | 60 | F8 | Hand M1 | 10 Hz | VAS, thermal sensory thresholds | Analgesic effect mainly in trigeminal nerve lesions |
(36 central NP; 24 peripheral NP) | 80% RMT | |||||||
1 | ||||||||
Khedr et al[25] | Trigeminal neuralgia and post-stroke pain syndrome | Double-blind, controlled | 48 | F8 | Hand M1 | 20 Hz | VAS and the LANSS scale | Analgesic effect |
(24 central NP; 24 trigeminal NP) | 80% RMT | |||||||
5 | ||||||||
André-Obadia et al[22] | Chronic refractory NP | Double-blind, controlled, crossover | 14 | F8 | Hand M1 | 1-20 Hz | VAS | Analgesic effect (only for 20 Hz) |
(11 central NP; 3 peripheral NP) | 90% RMT | |||||||
1 | ||||||||
Hirayama et al[104] | Intractable deafferentation pain | Double-blind, controlled, crossover | 20 | F8 | M1 | 5 Hz | VAS and SF-MPQ | Analgesic effect |
(14 central NP; 6 peripheral NP) | 90% RMT | |||||||
1 | ||||||||
Irlbarcher et al[117] | Chronic NP | Double-blind, controlled | 27 | F8 | M1 | 1-5 Hz | VAS | No effect |
(13 central NP; 14 phantom p) | 95% RMT | |||||||
5 | ||||||||
Lefaucheur et al[15] | Unilateral hand pain of various neurologic origins | Double-blind, controlled, crossover | 22 | F8 | Hand M1 | 10 Hz | Motor threshold at rest, MEP amplitude, CSP, ICI | ICI increase |
(14 central NP; 8 peripheral NP) | 90% RMT | |||||||
1 | ||||||||
Lefaucheur et al[118] | Chronic NP | Double-blind, controlled, crossover | 36 | F8 | Face M1 | 10 Hz | VAS | Analgesic effect with the stimulation applied on area adjacent to the cortical representation of the painful zone |
80% RMT | ||||||||
1 | ||||||||
Defrin et al[35] | Spinal cord injury | Double-blind, controlled | 12 | F8 | Vertex | 5 Hz | VAS, MPQ, pain threshold | Increased heat pain threshold |
115% RMT | ||||||||
10 | ||||||||
Passard et al[29] | Fibromyalgia | Double-blind, controlled | 30 | F8 | M1 | 10 Hz | VAS, MPQ, quality of life (Brief Pain Inventory and the Fibromyalgia Impact Questionnaire) | Decrease in VAS and better quality of life |
80% RMT | ||||||||
10 | ||||||||
Saitoh et al[115] | Intractable deafferentation pain | Double-blind, controlled, crossover | 13 | F8 | M1 | 1-5-10 Hz | VAS | Decrease in VAS (only for 5-10 Hz) |
(9 central NP; 4 peripheral NP) | 90% RMT | |||||||
1 | ||||||||
André-Obadia et al[119] | Chronic NP | Double-blind, randomized, controlled, crossover | 28 | F8 | M1 | 20 Hz | Pain relief, quality of life and rescue drug intake | Analgesic effect |
90% RMT | ||||||||
1 | ||||||||
Lefaucheur et al[120] | Chronic refractory NP | Double-blind, controlled, crossover | 46 | F8 | Hand M1 | 10 Hz | Thresholds for thermal and mechanical sensations | Thermal perception improvement |
(23 central NP; 23 peripheral NP) | 90% RMT | |||||||
1 | ||||||||
Carretero et al[121] | Fibromyalgia | Randomized, single-blinded | 28 | Butterfly coil | DLPFC | 1 Hz | FibroFatigue, Likert pain, HDRS, CBI | No effect |
110% RMT | ||||||||
20 | ||||||||
Kang et al[36] | Spinal cord injury | Double-blind, controlled, crossover | 11 | F8 | M1 | 10 Hz | NRS, BPI | No effect |
80% RMT | ||||||||
5 | ||||||||
Picarelli et al[33] | CRPS type 1 | Double-blind, controlled | 23 | F8 | M1 | 10 Hz | VAS, MPQ, the SF-36, HDRS | Analgesic effect and improved quality of life |
90% RMT | ||||||||
10 | ||||||||
Ahmed et al[108] | Phantom pain | Double-blind, controlled | 27 | F8 | DLPFC | 20 Hz | VAS, LANSS scale | Decrease in VAS and LANSS scale |
80% RMT | ||||||||
5 | ||||||||
Mhalla et al[38] | Fibromyalgia | Double-blind, controlled | 40 | F8 | M1 | 10 Hz | Pain intensity over the last 24 h, BPI, quality of life, mood and anxiety, parameters of motor cortical excitability | Analgesic effect |
80% RMT | ||||||||
Short et al[63] | Fibromyalgia | Double-blind, controlled | 20 | F8 | M1 | 14 | BPI, HDRS, Fibromyalgia Impact Questionnaire | Improvement of daily pain, number of tender points, HDRS and FIQ scores |
10 Hz | ||||||||
120% RMT | ||||||||
Lefaucheur et al[122] | Chronic refractory NP | Controlled, crossover | 14 | F8 | M1 | 10 | VAS | Analgesic effect |
(3 localized in the face, 4 upper limb, 3 lower limb, 4 hemibody) | 10 Hz | |||||||
90% RMT | ||||||||
3 | ||||||||
Hosomi et al[109] | NP | Double-blind, controlled, crossover | 64 | F8 | M1 | 50 Hz | VAS, SF-MPQ, PGIC, and BDI | Analgesic effect |
90% RMT | ||||||||
10 | ||||||||
Onesti et al[28] | Diabetic neuropathy | Double-blind, controlled, crossover | 23 | H-coil | Vertex | 20 Hz | VAS, area and threshold of RIII nociceptive flexion reflex RIII reflex | Decrease in VAS and RIII area |
100% RMT | ||||||||
5 | ||||||||
Jetté et al[34] | Spinal cord injury | Randomized, controlled, crossover | 16 | F8 | M1 | 10 Hz | VAS, motor mapping parameters | Decrease in VAS |
90%-110% RMT | ||||||||
3 | ||||||||
Boyer et al[30] | Fibromyalgia | Double-blind, randomized, controlled | 38 | F8 | M1 | 10 Hz | FIQ, SF-36, brain metabolism | Improvement of quality of life |
90% RMT | ||||||||
14 | ||||||||
Dall’Agnol et al[123] | Myofascial pain syndrome | Double-blind, randomized, controlled | 24 | F8 | M1 | 10 Hz | Pain quantitative sensory testing, conditioned pain modulation, TMS parameters, BDNF | Analgesic effect mediated by mechanisms enhancing the corticospinal inhibitory system and BDNF |
80% RMT | ||||||||
10 | ||||||||
Yılmaz et al[40] | Spinal cord injury | Double-blind, randomized, controlled | 17 | F8 | Vertex | 10 Hz | VAS | No effect |
110% RMT | ||||||||
10 | ||||||||
Hodaj et al[124] | Chronic refractory facial pain | Open-label study | 55 | F8 | Face M1 | 10 Hz | VAS, CGIC scale | Analgesic effect |
80% RMT | ||||||||
(19 cluster headache; 21 trigeminal neuropathic pain; 15 atypical facial pain) | 12 | |||||||
Khedr et al[125] | Malignant NP | Randomized, controlled | 34 | F8 | Hand M1 | 20 Hz | VDS, VAS, LANSS, HDRS | Analgesic effect |
80% RMT | ||||||||
10 | ||||||||
Lindholm et al[126] | Neuropathic orofacial pain | Randomized, controlled, cross-over | 16 | - | S1/M1, right SII | - | NRS, BPI | Analgesic effect (only for SII) |
Non-NP | ||||||||
Brighina et al[46] | Migraine | Double-blind, randomized, controlled | 11 | F8 | DLPFC | 10 Hz | Frequency of attacks, Headache index | Significant reduction of outcome measures |
90% RMT | ||||||||
12 | ||||||||
Pleger et al[48] | CRPS | Double-blind, controlled, crossover | 10 | F8 | M1 | 10 Hz | VAS | Analgesic effect |
110% RMT | ||||||||
1 | ||||||||
Borckardt et al[127] | Postoperative pain | Double-blind, controlled | 20 | F8 | Left PFC | 10 Hz | VAS for mood, opioid pump use | Reduction in opioid use |
100% RMT | ||||||||
1 | ||||||||
Johnson et al[49] | Low back pain | Double-blind, controlled, crossover | 17 | F8 | M1 | 20 Hz | Detection and pain thresholds for cold and heat sensations | Increased heat pain threshold and lowered cold detection |
95% RMT | ||||||||
1 | ||||||||
Fregni et al[50] | Pancreatitis | Double-blind, controlled | 17 | F8 | SII | 1 Hz | VAS, BDI | Analgesic effect |
70% RMT | ||||||||
10 - | ||||||||
Conforto et al[47] | Migraine | Randomized, double-blind, parallel-group | 18 | - | DLPFC | Number of headache days | No effect | |
Melchior et al[51] | Irritable bowel syndrome | Double-blind, controlled, crossover | 21 | F8 | M1 | 20 Hz | Pressure pain threshold, changes in maximum tolerated rectal volume, rectal compliance and average pain intensity | Maximun tolerated rectal volume and analgesic effects |
80% RMT | ||||||||
5 | ||||||||
Avery et al[52] | Chronic widespread pain | Double-blind, randomized, controlled | 19 | - | DLPFC | - | BIRS | No effect |
15 |
- Citation: Onesti E, Gori MC, Frasca V, Inghilleri M. Transcranial magnetic stimulation as a new tool to control pain perception. World J Anesthesiol 2016; 5(1): 15-27
- URL: https://www.wjgnet.com/2218-6182/full/v5/i1/15.htm
- DOI: https://dx.doi.org/10.5313/wja.v5.i1.15